Dialectic’s DT2216 Receives the US FDA’s Fast Track Designation for Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma
Shots:
- The US FDA has granted FTD to DT2216 for the treatment of adult patients with r/r PTCL and CTCL
- DT2216 is being evaluated in the P-I, dose-escalation study for advanced or metastatic solid tumors & hematologic malignancies that are no longer responsive to approved or accepted SoC interventions. DT2216 (BID) was given as IV for 4wks.
- In preclinical studies, DT2216 has selectively induced the degradation of B-cell lymphoma, or BCL-XL in cancer cells & stimulates the return of cellular apoptosis or sensitizes the cells to be more susceptible to CT. The therapy was effective in multiple in vitro models of hematologic & solid tumors as monothx. & in combination with other chemotherapeutic agents
Ref: PR Newswire | Image: Dialectic
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
